skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Resminostat (Code C84856)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Resminostat

Definition: An orally bioavailable inhibitor of histone deacetylases (HDACs) with potential antineoplastic activity. Resminostat binds to and inhibits HDACs leading to an accumulation of highly acetylated histones. This may result in an induction of chromatin remodeling, inhibition of the transcription of tumor suppressor genes, inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor types, are a class of enzymes that deacetylate chromatin histone proteins.

Label: Resminostat

NCI Thesaurus Code: C84856 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2935131  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)

External Source Codes: 
CAS Registry Number 864814-88-0 (see NLM ChemIDplus info)
FDA UNII Code 1578EUB98L
PDQ Closed Trial Search ID 651465
PDQ Open Trial Search ID 651465 (check for NCI PDQ open clinical trial info)
UMLS CUI C2935131

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C16H19N3O4S
code C84856
Contributing_Source FDA
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom